SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Tahir, H
Right arrow Articles by Isenberg, D A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tahir, H
Right arrow Articles by Isenberg, D A
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Novel therapies in lupus nephritis

H Tahir

Department of Medicine, University College London, Centre for Rheumatology, London, UK

D A Isenberg

Department of Medicine, University College London, Centre for Rheumatology, London, UK, d.isenberg{at}ucl.ac.uk

Renal disease continues to cause major morbidity and some mortality for around 30-40% of patients with systemic lupus erythematosus (SLE). Although the combinations of prednisolone and azathioprine or prednisolone and cyclophosphamide have been beneficial to many patients with SLE, they are not always effective and have significant side effects. It is very encouraging that new immunosuppressive drugs such as mycophenolate mofetil and more targeted therapies e.g., anti-CD20 are coming rapidly to larger scale clinical trials. The treatment of lupus nephritis is set to change quite rapidly in the next decade. In this review we highlight the likely major therapeutic advances.

Key Words: B cell depletion • cytokines • lupus nephritis • mycophenolate mofetil • systemic lupus erythematosus

Lupus, Vol. 14, No. 1, 77-82 (2005)
DOI: 10.1191/0961203305lu2064oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
Z Wang, Z Tang, H. Zhang, W. Hu, Z. Liu, and L. Li
Clinicopathological characteristics of familial SLE patients with lupus nephritis
Lupus, March 1, 2009; 18(3): 243 - 248.
[Abstract] [PDF]

Home page
 LupusHome page
E. MacDermott, A. Adams, and T. Lehman
Review: Systemic lupus erythematosus in children: current and emerging therapies
Lupus, August 1, 2007; 16(8): 677 - 683.
[Abstract] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. V. Navarra
Immune therapy of lupus: what is on the horizon?
Nephrol. Dial. Transplant., March 1, 2006; 21(3): 579 - 581.
[Full Text] [PDF]


Advertisement